GlassScriptPhysician profile
Juan C Armstrong
NPI 1639259666
$20,810.58
in general payments reported to CMS, 2019-2025
40 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,402 · 2020: $7,462 · 2021: $4,841 · 2022: $1,921 · 2023: $1,011 · 2024: $1,121 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.53 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14,988.35 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,108.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $854.59 | 2019-2025 | Ofev |
| Grifols USA, LLC | $540.43 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $371.98 | 2019-2025 | |
| Mylan Specialty L.P. | $346.84 | 2019-2024 | Yupelri |
| Amgen INC. | $286.95 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $147.76 | 2019-2022 | |
| Verona Pharma, INC. | $139.99 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Novo Nordisk INC | $73.34 | 2022-2023 | |
| Insmed, INC. | $70.82 | 2019-2024 | Arikayce |
| Ani Pharmaceuticals, INC. | $61.69 | 2024-2025 | Purified Cortrophin Gel |
| Vapotherm INC | $48.75 | 2022 | |
| Mallinckrodt Enterprises LLC | $45.64 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $44.20 | 2020-2024 | Giapreza |
| Janssen Pharmaceuticals, INC | $41.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.48 | 2022-2025 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $39.53 | 2019-2021 | |
| Electromed, INC. | $35.65 | 2019 | |
| Abbvie INC. | $35.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.04 | 2021-2022 | |
| Pulmonx Corporation | $31.81 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Shionogi INC | $31.48 | 2022 | |
| Pfizer INC. | $30.01 | 2020-2022 | |
| Baxter Healthcare | $26.90 | 2023 | Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $23.27 | 2023 | Opsumit |
| Mallinckrodt Hospital Products INC. | $20.94 | 2020 | |
| Cvrx, INC. | $19.55 | 2025 | Barostim Neo System |
| Viatris Specialty LLC | $19.47 | 2025 | Yupelri |
| Csl Behring | $16.82 | 2019 | |
| Genentech USA, INC. | $16.48 | 2019 | |
| Advanced Respiratory, INC | $16.11 | 2020 | |
| Shire North American Group INC | $15.74 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.36 | 2022 | |
| Resmed Corp | $15.15 | 2024 | |
| Paratek Pharmaceuticals, INC. | $14.99 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $14.27 | 2024 | Capvaxive |
| Phadia US INC. | $13.83 | 2020 | |
| Gilead Sciences, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.